Does Aetna Cover GLP-1 Medications? The 2026 Guide
Aetna's GLP-1 landscape shifted significantly in 2025 — Zepbound is now non-formulary on most plans. Here's what Aetna members in Washington need to know.
Aetna uses CVS Caremark as its pharmacy benefit manager — the company that actually manages formularies, processes prior authorizations, and determines tier placement for most Aetna commercial plans. In July 2025, CVS Caremark made a significant formulary change that affected millions of Aetna members: tirzepatide (Zepbound) was removed from the standard national formulary for obesity. This guide explains exactly what changed and what Washington state Aetna members need to know going into 2026.
At Revive Low T Clinic, we work with Aetna members navigating GLP-1 coverage regularly. The situation is more nuanced than headlines suggest — Zepbound removal only affects the obesity indication, not sleep apnea or diabetes. And for patients who need tirzepatide specifically, there are documented exception pathways. Here's the complete picture.
Aetna GLP-1 Coverage at a Glance
| Medication / Indication | Covered? | Key Requirements |
|---|---|---|
| Ozempic / Mounjaro (T2D) | Yes | T2D; PA per Aetna CPB 1014; 12-month approval; fertility counseling documentation |
| Wegovy (Obesity) | Plan-Dep. (Preferred) | AOM rider required; BMI ≥30 or ≥27 + comorbidity; PREFERRED product on CVS Caremark plans |
| Zepbound (Obesity) | Non-Formulary | REMOVED from CVS Caremark standard formulary July 2025; exception requires Wegovy trial ≥12–16 wks showing <5% loss OR semaglutide intolerance |
| Wegovy (CV Risk) | Yes | Established CVD + BMI ≥27; no AOM rider needed; PA required under CPB 1014 |
| Zepbound (OSA) | Yes | OSA + BMI ≥30; sleep study required; NOT affected by Zepbound formulary removal |
The 2025 Formulary Change: Why Zepbound Is Now Harder to Get on Aetna
This is the development that changed the landscape for Aetna GLP-1 coverage in 2025. In July 2025, CVS Caremark — Aetna's pharmacy benefit manager — removed Zepbound (tirzepatide) from its standard national formulary for weight management. This is not a minor change. It means that most Aetna commercial plan members can no longer receive Zepbound for obesity management at standard formulary rates.
As of July 2025, CVS Caremark removed Zepbound from its standard national formulary. This affects most Aetna commercial plans. Patients seeking tirzepatide (Zepbound) for weight management now need either: (1) a documented Wegovy trial of 12–16 weeks showing less than 5% weight loss, OR (2) documented intolerance or medical contraindication to semaglutide.
Why did this happen? CVS Caremark and Novo Nordisk struck a preferred placement deal for Wegovy. In exchange for preferred formulary positioning — and presumably favorable pricing negotiated on behalf of their plan sponsors — CVS Caremark moved tirzepatide to non-formulary status. Patients who are already on Zepbound through Aetna may be able to request a continuity exception to avoid disruption, though this is not guaranteed and depends on the specific employer plan.
Wegovy Is Now the Preferred GLP-1 at Aetna/CVS
Wegovy (semaglutide) is now Aetna's preferred weight management GLP-1 product on CVS Caremark-managed plans. If you have an AOM (anti-obesity medication) rider on your Aetna plan and meet the BMI criteria — BMI ≥30, or BMI ≥27 with a qualifying comorbidity — Wegovy is the path of least resistance. It sits on the standard formulary, PA requirements are straightforward, and your copay applies.
Zepbound, by contrast, requires extra steps before Aetna will approve it. From a clinical standpoint, both drugs work well for weight management. Zepbound (tirzepatide) studies generally show marginally better average weight loss outcomes compared to semaglutide at equivalent doses — but Wegovy is highly effective, extensively studied, and costs the same copay on plans where it's preferred. If your goal is medically supervised weight loss and Wegovy is accessible on your plan, it is a legitimate and effective first-line option.
The Exception Process for Zepbound
When the standard formulary path is blocked, there are two documented ways to get Zepbound approved on Aetna. Neither is guaranteed, but both have clear criteria that a provider can document:
- Document a failed Wegovy trial: You must show less than 5% weight loss after 12–16 weeks at therapeutic dose. The trial must be documented with start and end weights, dosing records, and a clinical note confirming adherence. Weight loss below the 5% threshold — despite compliant use — qualifies as inadequate response.
- Document clinical contraindication to semaglutide: Persistent nausea or vomiting preventing dose escalation beyond initial doses, a documented thyroid concern (e.g., personal or family history of MEN 2 or medullary thyroid carcinoma), or another clinically documented intolerance can serve as the basis for the exception request.
The exception request is submitted with a clinical narrative through CVS Caremark's prior authorization portal. Standard processing takes 5–10 business days. At Revive, we prepare complete exception packages including clinical narrative, lab documentation, weight tracking records, and dosing history when applicable.
The OSA Pathway: Zepbound Unaffected
One important clarification that gets lost in the Zepbound formulary removal news: the July 2025 CVS Caremark change only affects Zepbound when prescribed for obesity. The OSA coverage pathway for Zepbound is completely separate — and was not touched by that formulary decision.
Aetna members who need tirzepatide: the sleep apnea coverage pathway for Zepbound is completely separate from the obesity formulary and was not affected by the July 2025 CVS Caremark change. If you have moderate-to-severe obstructive sleep apnea confirmed by sleep study plus BMI ≥30, Zepbound via the OSA indication is still approved through Aetna's standard PA process.
This is a meaningful pathway for many patients. Obesity and obstructive sleep apnea are highly correlated — a significant portion of patients seeking GLP-1 therapy for weight management also have documented sleep apnea. If you have a prior sleep study showing AHI ≥15 and a BMI ≥30, Zepbound for OSA may be accessible on your Aetna plan even if Zepbound for obesity is not.
Prior Authorization and CPB 1014
Aetna's GLP-1 prior authorization requirements are governed by Clinical Policy Bulletin (CPB) 1014 and administered through CVS Caremark's PA portal. The specific criteria vary by indication:
- For T2D (Ozempic/Mounjaro): Documented T2D diagnosis, HbA1c at or above 7%, prior treatment history (typically metformin unless contraindicated), and prescriber documentation of clinical management.
- For obesity (Wegovy): AOM rider on the plan, BMI ≥30 or BMI ≥27 with at least one qualifying comorbidity, documentation of lifestyle modification counseling, and clinical narrative from the prescriber.
- For cardiovascular risk (Wegovy): Established cardiovascular disease — prior MI, prior stroke, or symptomatic PAD — plus BMI ≥27. No AOM rider required. PA required under CPB 1014 but often faster to approve than obesity pathway.
- For OSA (Zepbound): Sleep study confirming AHI ≥15, BMI ≥30, obstructive (not central) apnea confirmed on study. PA submitted through CVS Caremark.
PA submissions to Aetna go through CVS Caremark's prior authorization portal. Standard approval timeline for complete submissions: 3–5 business days. Our team handles all PA submission documentation and follow-up.
Estimated Patient Costs
T2D (Ozempic / Mounjaro)
Specialty Tier; formulary PA required.
Wegovy (Obesity, with AOM rider)
Preferred Specialty; AOM rider must be active on plan.
Zepbound (Obesity)
Full OOP unless exception granted via Wegovy trial failure or semaglutide intolerance.
Wegovy (CV Risk)
Established CVD required; no AOM rider needed.
Common Questions From Aetna Members
Will my Aetna plan cover Zepbound?
For obesity: probably not on the standard formulary as of mid-2025. CVS Caremark removed Zepbound from the standard obesity formulary, and Wegovy is now the preferred product. However, Zepbound is still accessible via a documented failed Wegovy trial or semaglutide intolerance. For sleep apnea (OSA) or cardiovascular risk: yes, via those separate and unaffected pathways. For diabetes (Mounjaro brand): yes.
Can I stay on Zepbound if I was already on it?
Possibly. Aetna may grant continuity exceptions for patients who were already on Zepbound before the July 2025 formulary change. This is not automatic — your prescriber needs to submit a continuity exception request with documentation of your prior treatment. Contact your prescriber as soon as possible if you're concerned about disruption.
Is Wegovy or Zepbound better for weight loss?
Head-to-head clinical trial data (the SURMOUNT-5 trial) shows tirzepatide (Zepbound) produces marginally better average weight loss than semaglutide (Wegovy) at equivalent treatment durations. However, Wegovy is fully accessible on Aetna plans with AOM riders, is highly effective, and is extensively studied. The most effective medication is the one that is accessible, affordable, and tolerated well. For most Aetna members in 2026, starting with Wegovy is the practical first step.
Related GLP-1 Coverage Guides
Aetna Member? We Navigate CVS Caremark Formularies.
We know exactly what Aetna's CVS Caremark formulary requires in 2026. We'll find your best GLP-1 coverage pathway and handle the prior authorization start to finish.
Or call us: (206) 960-4770 · Seattle · Kirkland · Federal Way